Apogee Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Apogee Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2022 to Q2 2024.
  • Apogee Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$44.1M, a 134% decline year-over-year.
  • Apogee Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$144M.
  • Apogee Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$93M, a 203% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$144M -$44.1M -$25.2M -134% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$119M -$38.2M -$25.5M -202% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$93M -$37.2M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 -$24.3M -$13.8M -131% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$18.9M -$17.1M -940% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$12.7M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q3 2022 -$10.5M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$1.82M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.